U.S. Household Products Stock News

Bank of America stock has returned 136.3% over the past three years, and current valuation checks suggest the intrinsic value estimate still sits above the market price. This raises the question of how much of the recent optimism is already reflected in today’s US$63.89 share price. A 136.3% gain over three years shows that Bank of America has rewarded investors strongly, which can increase the risk that expectations in the price get ahead of the fundamentals. The planned US$250b Critical...

Tariff threats between the US and Canada have shifted from background noise to a real risk, with new duties of up to 50% on about $20b of cross border trade now on the table. That puts logistics and customs brokers directly in the spotlight. For investors, this could reshape who handles the flow of goods. This article walks through three stocks exposed to the latest trade shock and explains why they may matter for a diversified portfolio. The stocks in the article below are only a starting...

Elastic stock has rallied over the past few years, but long term holders are still facing a decline over five years. Current checks also show an unusual split between its intrinsic value estimate from a Discounted Cash Flow (DCF) model and what the market multiples suggest. The DCF points to Elastic trading at a discount to an estimated intrinsic value, yet the market based multiples appear expensive, leaving investors weighing which signal to trust. Over the last five years, Elastic shares...

The upcoming second quarter earnings report for Target (TGT) is in focus as investors look for evidence that the recent improvement in comparable sales and the retailer's broader turnaround efforts can continue. See our latest analysis for Target. Target's recent share price return of 50.24% year to date and 18.68% over 90 days points to strong positive momentum. However, the 5 year total shareholder return of a 30.12% decline highlights how long term holders have experienced a very different...

Astrana Health (ASTH) drew investor attention after releasing second quarter 2026 results and fresh guidance, alongside plans for further tuck in acquisitions in its Care Delivery expansion markets. See our latest analysis for Astrana Health. Astrana Health's recent earnings beat and updated 2026 guidance appear to be feeding into a strong year to date share price return of 57.61%. However, the 30 day share price return is down 11.55% and the 5 year total shareholder return is down 44.72%,...

In the past quarter, QCR Holdings reported revenue growth of 13.4% year on year, beating analyst expectations, while strong loan production, a rebound in capital markets revenue, and wealth management contributions helped deliver record GAAP EPS alongside lower-than-anticipated noninterest expenses. This performance highlights how QCR Holdings’ diversified banking and fee-based businesses can support earnings resilience when multiple segments contribute simultaneously to revenue and cost...

Virtu Financial recently launched notional order execution capabilities for 10b-18 corporate buyback programs, enabling clients to execute repurchases based on specific dollar amounts for tighter budget control and flexible commission treatment. Truist Bank’s internal analysis indicated that Virtu’s new notional execution outperformed a competing provider on benchmark quality and total notional value executed, highlighting the product’s differentiation in a niche market. We’ll now examine...

American Superconductor stock has retreated 39.9% over the past year, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) model currently points to around 12.5% upside from the recent share price of US$32.13. With market multiples also screening the stock as undervalued, investors are weighing whether the recent pullback has moved the price below what the cash flow outlook implies. Over the last 3 years, American Superconductor has returned 254.2%. This means long term...

With 30 year and 10 year Treasury yields pushing toward levels not seen in decades, the bond market is quietly rewriting the playbook for investors. Higher long term rates can pressure many stocks, yet they can also reshape the income potential and risk profile of others. This article looks at how that backdrop ties into three U.S. life insurers and annuity providers exposed to these yield moves, and what that could mean for your watchlist. The three stocks covered below are only a starting...

Why Paylocity’s latest earnings and partnerships matter for investors Paylocity Holding (PCTY) has been in focus after reporting fourth quarter and full year 2026 earnings alongside new partnerships that tie its human capital platform more tightly into AI driven recruiting tools. The company’s recent collaboration with HireQuotient and RocketReach links Paylocity’s cloud based HR, payroll and spend management suite to data powered sourcing and screening. This lets customers automate parts of...

StepStone Group (STEP) is back in focus after reporting first quarter results for the period ended June 30, 2026. The company posted higher revenue alongside a wider net loss that may raise fresh questions for investors. See our latest analysis for StepStone Group. Despite the wider loss in the latest quarter, StepStone Group’s share price has risen 10.86% over the past month, although the share price is still down 27.52% year to date and the 1 year total shareholder return is down 16.18%,...

Walmart stock has delivered a strong 142.1% total return over the past five years, while the latest valuation work using a Discounted Cash Flow (DCF) approach suggests the shares trade at a premium to that intrinsic value estimate. Over five years, Walmart has returned 142.1%, which puts recent gains under the spotlight as investors assess how much future cash flow is already reflected in the price. Growth expectations around e-commerce, advertising and automation partnerships such as the...

Eli Lilly stock has delivered a very large 5 year return while valuation checks now give a more mixed read. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside compared with a share price that already embeds high expectations. Eli Lilly has returned about 362.3% over 5 years, which puts extra focus on whether current holders are paying a premium for that track record. Expectations around long term demand for its obesity and diabetes treatments can support...

Earlier this year, DexCom highlighted that expanded insurance reimbursement now gives its continuous glucose monitoring systems access to a large group of type 2 non-insulin diabetes patients, while recent Q2 clinical data and product updates underscored the medical benefits of broader CGM use. This combination of wider coverage and strong evidence base is reshaping expectations for DexCom’s long-term demand profile and business mix, even as competition and pricing uncertainties remain...

Vera Therapeutics, Inc. reported past second quarter 2026 results showing a net loss of US$109.47 million, up from US$76.53 million a year earlier, with basic loss per share from continuing operations widening to US$1.52 from US$1.20. For the first half of 2026, the company’s net loss rose to US$230.51 million from US$128.23 million, highlighting a materially higher cash burn and pressure on per-share results at this stage of its development. Next, we will examine how this widening net loss...

Over the last 7 days, the United States market has remained flat, but it is up 19% over the past year with earnings expected to grow by 17% per annum over the next few years. In this context of steady growth and optimistic projections, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and potential for expansion in a dynamic industry landscape.

In the last week, the United States market has stayed flat, yet it has experienced a notable 19% increase over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of steady growth and positive earnings outlooks, identifying undervalued stocks can present opportunities for investors to capitalize on potential market inefficiencies.

Over the last 7 days, the United States market has remained flat, yet it is up 19% over the past year with earnings forecasted to grow by 17% annually. In this environment, growth companies with high insider ownership can be appealing as they often align management's interests with those of shareholders, potentially driving long-term value.

In the last week, the market has stayed flat, but it is up 19% over the past year with earnings expected to grow by 17% annually. For investors seeking opportunities beyond traditional stocks, penny stocks — a term that may seem outdated yet remains relevant — can provide access to smaller or less-established companies with potential for growth. By focusing on those with robust financials and a clear growth trajectory, investors might uncover promising prospects within this niche segment of...

Tariffs on Canadian autos and the threat of wider counter moves are reshaping how vehicles and parts move across the border, and that puts freight routes and rail lines under the spotlight. Investors watching this Canada and U.S. auto trade story may see both pressure and possibility as supply chains adjust. This article walks through three stocks that appear exposed to this news and explains why the market is paying attention now. The three stocks below are just a starting sample, and the...

Virtus Investment Partners has converted the Zevenbergen Growth Fund and Zevenbergen Genea Fund into the actively managed Virtus Zevenbergen Innovative Growth ETF (ZINN) and Virtus Zevenbergen Discovery Growth ETF (ZDIS), expanding its ETF lineup while retaining Zevenbergen Capital Investments’ high-growth equity strategies. This move shifts Zevenbergen’s growth approach into an ETF structure that offers intraday trading, full portfolio transparency, and potential tax efficiencies for...

Why the TETON-PPF milestone matters for United Therapeutics stock United Therapeutics (UTHR) has reached full enrollment in its 754 patient TETON-PPF phase 3 trial of nebulized Tyvaso for progressive pulmonary fibrosis, a key step toward potential label expansion. This milestone gives you a clearer timetable for the next catalyst. Topline data are expected in the second half of 2027, and the company has flagged the study as a basis for a possible supplemental FDA filing. See our latest...

Fresh commentary on CubeSmart (CUBE) has put its dividend profile, growth potential, and exposure to migration trends in focus as investors reassess self storage REITs and look for income opportunities in the sector. See our latest analysis for CubeSmart. CubeSmart’s share price has climbed 16.21% year to date to US$41.14, with a 90 day share price return of 5.60% and a 1 year total shareholder return of 11.53%. This points to gradually improving momentum as investors react to commentary...

Interparfums (IPAR) is back on investors’ radar after affirming a regular quarterly dividend of $0.80 per share, updating its buyback activity, and reporting second quarter earnings alongside full year 2026 guidance. See our latest analysis for Interparfums. Interparfums’ recent dividend affirmation, buyback update, and earnings release come after a period where the share price has risen 30.8% year to date, while the 1 year total shareholder return is 2.3%. Near term momentum has been strong,...